This is a summary of the European public assessment report (EPAR) for Adrovance. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adrovance.
Therapeutic Indication
### Therapeutic indication Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Adrovance reduces the risk of vertebral and hip fractures.
Therapeutic Area (MeSH)
ATC Code
M05BB03
ATC Item
alendronic acid and colecalciferol
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| colecalciferol | N/A | 维生素D3 |
| alendronic acid (as sodium trihydrate) | N/A | alendronic acid (as sodium trihydrate) |
EMA Name
Adrovance
Medicine Name
Adrovance
Aliases
N/ANo risk management plan link.
